QGEN · Qiagen N.V.

QIAGEN N.V. released its unaudited U.S. GAAP quarterly results for the period ended March 31, 2026, showing modest net sales growth to $492.3 million from $483.5 million in the prior-year quarter, driven by the company's Sample to Insight solutions in life sciences and molecular diagnostics. However, profitability declined significantly, with net income dropping 25% to $68.0 million and diluted EPS to $0.33 from $0.41, primarily due to elevated operating expenses totaling $225.2 million versus $193.3 million last year. Key pressures included a sharp rise in restructuring, acquisition, integration, and other costs to $32.2 million from $9.8 million, alongside increases in sales and marketing to $114.6 million and R&D to $48.3 million. Income from operations fell to $84.4 million from $115.3 million, reflecting margin compression amid these expenses. Other income netted positively at $1.4 million, but income tax expense of $17.8 million contributed to the lower bottom line. Balance sheet highlights include cash and equivalents at $646.3 million, down from $839.0 million at year-end 2025, following a major $496.7 million capital repayment that reduced common shares outstanding and equity to $3.3 billion. Operating cash flow remained solid at $100.6 million, supported by investing inflows of $211.5 million mainly from short-term investment redemptions, though financing outflows exceeded $503.7 million. Recent acquisitions of Parse Biosciences in December 2025 and Genoox in May 2025 are integrated, with their results contributing post-acquisition dates. Comprehensive income was $48.5 million, impacted by $19.5 million in other comprehensive loss from foreign currency translation and hedges. These results underscore ongoing integration costs and capital return priorities affecting near-term earnings.